

ACADIA PHARMACEUTICALS INC.

ISIN: US0042251084 WKN: 004225108 Asset Class: Stock

Company

2024/04/16 22:00:00



Price

17.08

USD

Difference



1.12%(0.19)



Contact Details

ACADIA PHARMACEUTICALS INC.

Tel: +1-858-558-2871

--

Fax: +

12830 El Camino Real, Suite 400

Web: <http://www.acadia.com>

92130-3331 San Diego

E-mail: info@acadia-pharm.com

Company Profile

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	616,125,000		507,937,000		617,823,000	
Common stock capital		16,000		16,000		16,000
Fixed assets	132,831,000		79,875,000		82,299,000	
Equity capital of a company		431,755,000		400,413,000		540,894,000
Cash and cash equivalents	188,657,000		114,846,000		147,435,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		254,254,000		125,630,000		96,068,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		62,947,000		61,769,000		63,160,000
Different income		-		-		-
Other liabilities		15,147,000		9,074,000		7,034,000
Total assets	748,956,000	748,956,000	587,812,000	587,812,000	700,122,000	700,122,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	598	513	514
Equity ratio	57.65%	68.12%	77.26%
Debt-equity ratio	73.47%	46.80%	29.44%

Others

	2023	2022	2021
Tax Expense Rate	-20.08%	-1.19%	-0.21%

ACADIA PHARMACEUTICALS INC.

ISIN: US0042251084 WKN: 004225108 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	726,437,000	517,235,000	484,145,000
Net income	-61,286,000	-215,975,000	-167,870,000
EBIT	-63,648,121	-205,156,344	-156,728,953
Operating income before taxes	-51,036,000	-213,444,000	-167,519,000
Cash Flow	16,702,000	-114,035,000	-125,660,000
Net interest income	17,234,000	6,610,000	591,000
Research and development expenses	351,619,000	361,575,000	239,415,000
Income taxes	10,250,000	2,531,000	351,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,132,537	939,996	878,149

Board of Directors

Members of Management Board

Stephen Biggar	Chairman of Board of Directors
Adora Ndu	Member of Board of Directors
Edmund Harrigan	Member of Board of Directors
Elizabeth Garofalo	Member of Board of Directors
Daniel Soland	Member of Board of Directors
James Daly	Member of Board of Directors
Julian Baker	Member of Board of Directors
Laura Brege	Member of Board of Directors